Medicxi increases stake in Cambridge biotech Bplete Limited
Published
Bplete Limited, a Cambridge-based biotechnology firm founded in 2021, has recorded a substantial increase in shareholdings by its existing investors. Medicxi III LP expanded its position in the company by 194 percent, growing its holding from 1,967 shares to 5,777 shares. Medicxi Co-Invest III LP also increased its stake by 197 percent, moving from 33 shares to 98 shares.
The changes were detailed in a confirmation statement filed on 3 June 2026. These stake increases by multiple entities associated with the same investment group may signal a recent round of funding. Bplete Limited focuses on research and experimental development within the biotechnology sector, including work on bioinformatics, cell and tissue culture, and gene and RNA vectors.
The Foundry (Cambridge) Limited has exited the cap table, having previously held zero shares at the start of the period. Medicxi III LP and Medicxi Co-Invest III LP remain the key shareholders following these transactions. The company operates from Cambridge and conducts research into nanobiotechnology and protein molecules. This update confirms the current state of the company ownership as of June 2026.
Shareholder data
Source: Companies House confirmation statement (CS01) — period to , filed .
Changes in this confirmation statement
| Type | Shareholder | Shares | Change | Share classes |
|---|---|---|---|---|
| Exited | THE FOUNDRY (CAMBRIDGE) LIMITED | 0 | — | ORDINARY 0 |
| Increased | MEDICXI III LP | 5,777 | +194% | ORDINARY 5,777 |
| Increased | MEDICXI CO-INVEST III LP | 98 | +197% | ORDINARY 98 |
Current shareholders (2)
| Shareholder | Total shares | Share classes |
|---|---|---|
| MEDICXI III LP | 5,777 | ORDINARY 5,777 |
| MEDICXI CO-INVEST III LP | 98 | ORDINARY 98 |
Contact the editorial team at [email protected]